Zhiming Cai

Zhiming Cai is a Visiting Professor at the National Cancer Institute (NCI) and holds multiple leadership roles in China, including President of Shenzhen Medical Association, Deputy Director of Carlson International Oncology Center at Shenzhen University, and Director of the Guangdong Key Laboratory of Systemic Biology and Synthetic Biology in Genitourinary Oncology. As an Outstanding Principal Investigator at the Chinese Academy of Science's Institute of Synthetic Biology, he leads groundbreaking research in cancer genomics and synthetic biology.

• Doctor Philosophiae Honoris Causa, The National Academy of Science of Ukraine
• Fellow, American Institute for Medical and Biological Engineering (AIMBE)

His research focuses on synthetic biology applications for cancer therapy, including engineered cell treatments and artificial gene circuits for tumor targeting. Notable work includes the "Remodeling Tumor Suppressor Theory" and CRISPR-based signal transduction systems that earned recognition from Nobel laureates and top-tier journals.

With over 330 publications and an H-Index of 36, Cai's work has appeared in Nature, Cell, and European Urology. His research team has successfully treated over 200 advanced tumor patients using synthetic biology approaches, demonstrating clinical translation of cutting-edge technology.

• Guangdong Medical Natural Science Award (First Class)
• May 1st Labor Medal (China's highest worker award)
• State Council Special Allowance Expert
• National Model Worker
• International Genetically Engineering Machine Competition Gold Award

Cai directs multiple high-profile research institutions including the National Tumor Genome Application Engineering Laboratory and the Academic Committee of the National and Local Joint Medical Synthetic Biology Engineering Laboratory. His work bridges basic research with clinical applications in genitourinary oncology through systematic biology approaches.